Humanin: Benefits & Research

Humanin is one of the first mitochondrial-derived peptides (MDPs) discovered — a class of small bioactive peptides encoded within mitochondrial DNA rather than nuclear DNA. This discovery in 2001 fundamentally changed our understanding of mitochondria, revealing them as signaling organelles that communicate with the rest of the cell through peptide messengers.

Humanin exerts its effects through multiple identified receptors and pathways:

• FPRL1/FPRL2 receptors: G-protein-coupled receptors that mediate anti-inflammatory and cytoprotective signaling
• BAX binding: Humanin directly binds the pro-apoptotic protein BAX, preventing it from triggering mitochondrial membrane permeabilization — the point of no return in programmed cell death
• IGFBP-3 interaction: Humanin binds insulin-like growth factor binding protein 3, modulating IGF-1 signaling and cell survival
• STAT3 activation: Downstream signaling through the JAK/STAT3 pathway promotes cell survival gene expression
• TRIM11 binding: Recently identified receptor that mediates humanin's metabolic effects

The net effect is a powerful anti-apoptotic and cytoprotective signal — humanin tells cells to survive rather than undergo programmed death. This is relevant because excessive apoptosis contributes to aging, neurodegeneration, cardiovascular disease, and metabolic dysfunction.

Humanin is part of the same mitochondrial peptide family as MOTS-c, though they have different primary mechanisms: humanin is cytoprotective while MOTS-c is metabolic (AMPK activation).

Humanin was discovered in the surviving neurons of Alzheimer's disease brains — neurons that had resisted the neurodegenerative process. This origin story directly connects humanin to neuroprotection.

Research findings in neurological models:

• Amyloid-beta protection: Humanin (and more potently, HNG) protected neurons from amyloid-beta toxicity — the hallmark pathological protein of Alzheimer's disease. This was the original finding that led to humanin's discovery
• Cognitive preservation in aging: Yen et al. (2018) demonstrated that humanin prevented age-related cognitive decline in mice. Circulating humanin levels were positively correlated with better cognitive performance in elderly humans
• Familial Alzheimer's protection: Humanin was effective against neurotoxicity caused by multiple familial Alzheimer's disease-causing mutations (presenilin 1, presenilin 2, and APP mutations)
• Broader neurodegeneration: Protective effects have been observed in models of prion disease, Huntington's disease, and cerebral ischemia (stroke)

Declining humanin with age: Endogenous humanin levels decrease significantly with aging. Studies have shown that circulating humanin levels are approximately 40% lower in elderly adults compared to young adults. This age-related decline may contribute to the increasing vulnerability of aged neurons to apoptotic stress.

For other neuroprotective peptides, see cerebrolysin (multi-neurotrophic, clinical RCTs), semax (BDNF modulation), and dihexa (HGF/synaptogenesis). Visit the cognitive enhancement guide for a comprehensive overview.

Beyond neuroprotection, humanin has demonstrated significant metabolic regulatory effects:

Insulin Sensitivity

Muzumdar et al. (2009) showed that humanin acts as a central and peripheral regulator of insulin action:

• Intracerebroventricular administration of humanin improved whole-body insulin sensitivity in rodents
• Peripheral administration improved hepatic insulin sensitivity and glucose homeostasis
• Effects were mediated through hypothalamic STAT3 signaling, connecting brain humanin signaling to peripheral metabolism

Glucose Homeostasis

• Humanin improved glucose tolerance in diet-induced obesity models
• Reduced hepatic glucose output — a key driver of fasting hyperglycemia in type 2 diabetes
• Enhanced skeletal muscle glucose uptake independent of insulin signaling

Body Composition

• Humanin administration reduced visceral fat accumulation in high-fat diet-fed rodents
• Reduced triglyceride levels and improved lipid profiles
• Effects were independent of food intake — humanin did not significantly alter appetite

These metabolic findings position humanin alongside MOTS-c as a mitochondrial-derived metabolic regulator. The two peptides work through complementary mechanisms: MOTS-c activates AMPK directly, while humanin modulates insulin signaling through STAT3 and IGFBP-3 pathways. See the fat loss peptides guide for broader metabolic optimization strategies.

Humanin has demonstrated cardioprotective effects in multiple animal models:

• Ischemia-reperfusion protection: Humanin reduced infarct size (area of dead heart tissue) in rodent models of heart attack. It prevented cardiomyocyte apoptosis during the reperfusion phase — when blood flow returns and triggers a burst of oxidative stress
• Atherosclerosis modulation: Humanin reduced atherosclerotic plaque formation in ApoE-knockout mice (a standard model of cardiovascular disease). Effects were attributed to reduced macrophage apoptosis within plaques and improved endothelial function
• Endothelial protection: Humanin protected vascular endothelial cells from oxidative stress-induced apoptosis, potentially preserving blood vessel function during aging
• Cholesterol metabolism: Preliminary data suggests humanin may modulate cholesterol efflux and foam cell formation within arterial walls

The cardiovascular applications of humanin are at an early research stage. No human cardiovascular trials have been conducted. However, the connection between mitochondrial dysfunction, cellular apoptosis, and cardiovascular disease is well-established, and humanin's anti-apoptotic mechanism addresses this fundamental pathology.

Humanin sits at the intersection of several key aging pathways, making it one of the most researched peptides in the longevity field:

Age-Related Decline

Endogenous humanin levels decline with age across species studied:

• Humans: ~40% decline in circulating humanin from young adulthood to old age
• Rodents: Proportional age-related decline in tissue and plasma humanin
• Correlation with aging phenotypes: Lower humanin levels are associated with worse cognitive function, increased insulin resistance, and higher markers of cellular stress in human studies

Mitochondrial Quality Control

By preventing excessive mitochondrial-mediated apoptosis, humanin may help maintain the cellular population during aging. Age-related cell loss — in the brain, heart, muscle, and other tissues — is driven partly by increased apoptotic signaling that humanin counteracts.

Growth Hormone Axis Interaction

Interesting research from the Longo and Cohen labs has shown that humanin levels are inversely correlated with growth hormone (GH) and IGF-1 levels. GH receptor knockout (GHRKO) mice — which live significantly longer than normal mice — have elevated humanin levels. This connection between reduced GH/IGF-1 signaling, elevated humanin, and lifespan extension is an active area of longevity research.

Integration with Anti-Aging Protocols

Humanin is often incorporated into comprehensive longevity protocols alongside:

• Epitalon — telomerase activation for cellular lifespan
• NAD+ — mitochondrial energy production and sirtuin activation
• MOTS-c — metabolic optimization via AMPK
• GHK-Cu — tissue remodeling and gene expression

See the anti-aging peptides guide and the longevity stack for structured protocols.

Feature	Humanin (HNG)	MOTS-c
Source	16S rRNA gene (mtDNA)	12S rRNA gene (mtDNA)
Size	24 amino acids	16 amino acids
Primary mechanism	Anti-apoptotic (BAX binding, STAT3)	AMPK activation, metabolic regulation
Main benefits	Cytoprotection, neuroprotection, insulin sensitivity	Exercise mimetic, fat loss, glucose regulation
Key application	Anti-aging, neurodegeneration	Metabolic health, body composition
Evidence level	Preclinical + human correlational data	Preclinical + early human trials
Route	Subcutaneous injection	Subcutaneous injection
Age-related decline	Yes (~40% reduction)	Yes (significant reduction)

Key insight: Humanin and MOTS-c are complementary rather than redundant. Humanin protects existing cells from death; MOTS-c optimizes metabolic function in living cells. Together, they address two fundamental aspects of aging: cell loss and metabolic decline.